Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRC022
MIFTS: 42

Tricuspid Valve Insufficiency

Categories: Cardiovascular diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Tricuspid Valve Insufficiency

About this section

MalaCards integrated aliases for Tricuspid Valve Insufficiency:

Name: Tricuspid Valve Insufficiency 12 44 15 73
Tricuspid Regurgitation 12 29 55 6 15
Tricuspid Valve Regurgitation 12
Tricuspid Incompetence 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4080
MeSH 44 D014262
UMLS 73 C0040961
Sources

Summaries for Tricuspid Valve Insufficiency

About this section
Disease Ontology : 12 A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal.

MalaCards based summary : Tricuspid Valve Insufficiency, also known as tricuspid regurgitation, is related to constrictive pericarditis and mitral valve stenosis. An important gene associated with Tricuspid Valve Insufficiency is PTPN11 (Protein Tyrosine Phosphatase, Non-Receptor Type 11). The drugs Propafenone and Sotalol have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Tricuspid Valve Insufficiency

About this section

Diseases in the Tricuspid Valve Disease family:

Tricuspid Valve Insufficiency

Diseases related to Tricuspid Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 constrictive pericarditis 30.7 ALB NPPB
2 mitral valve stenosis 30.7 ACVRL1 CRELD1 NPPB
3 heart disease 30.5 ALB CRELD1 NPPB PTPN11 ZIC3
4 tetralogy of fallot 30.4 CRELD1 FBN1 NPPB PTPN11
5 mitral valve insufficiency 30.4 CRELD1 FBN1 NPPB PDZK1IP1
6 pulmonary hypertension, primary, 1 30.3 ACVRL1 FBN1 NPPB
7 pulmonary valve stenosis 30.2 CRELD1 PTPN11
8 aortic valve insufficiency 30.0 FBN1 NPPB
9 tricuspid valve stenosis 30.0 ARSE CA6 CRELD1 FBN1
10 aortic valve disease 1 29.9 CRELD1 FBN1 NPPB
11 arteries, anomalies of 29.9 ACVRL1 ALB NPPB
12 mitral valve disease 29.9 CRELD1 FBN1
13 heart valve disease 29.5 ARSE CRELD1 FBN1 NPPB PDZK1IP1
14 tricuspid valve disease 28.7 ACVRL1 ARSE CRELD1 FBN1 MC3R NPPB
15 atrial fibrillation 10.5
16 ventricular septal defect 10.5
17 endocarditis 10.4
18 pericarditis 10.3
19 sickle cell disease 10.3
20 congestive heart failure 10.3
21 varicose veins 10.2
22 atrioventricular block 10.2
23 rheumatic heart disease 10.2
24 patent foramen ovale 10.2
25 pulmonary embolism 10.2
26 cardiac tamponade 10.2 ACVRL1 NPPB
27 pulmonary valve disease 10.2 CRELD1 PTPN11
28 toxic myocarditis 10.2 NPPB ZIC3
29 down syndrome 10.1
30 sickle cell anemia 10.1
31 dilated cardiomyopathy 10.1
32 hyperthyroidism 10.1
33 cardiogenic shock 10.1
34 noma 10.1 ALB PTPN11
35 pulmonic stenosis 10.1 PTPN11 ZIC3
36 chylothorax, congenital 10.1 ALB PTPN11
37 patent ductus arteriosus 1 10.1 CRELD1 NPPB PTPN11
38 syndrome of inappropriate antidiuretic hormone 10.1 ALB NPPB
39 thyroid crisis 10.1 ALB ZIC3
40 heart septal defect 10.1 ACVRL1 CRELD1
41 renal hypertension 10.1 ALB NPPB
42 cardiac valvular defect, developmental 10.0
43 orthostatic intolerance 10.0
44 kawasaki disease 10.0
45 beta-thalassemia 10.0
46 acute myocardial infarction 10.0
47 thalassemia 10.0
48 venous insufficiency 10.0
49 pulmonary valve insufficiency 10.0
50 hypertrophic cardiomyopathy 10.0

Graphical network of the top 20 diseases related to Tricuspid Valve Insufficiency:



Diseases related to Tricuspid Valve Insufficiency
Sources

Symptoms & Phenotypes for Tricuspid Valve Insufficiency

About this section

GenomeRNAi Phenotypes related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.64 MC3R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.64 ACVRL1 CPB1 MC3R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.64 ACVRL1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.64 CPB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.64 MC3R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.64 ACVRL1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.64 MC3R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.64 ACVRL1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.64 CPB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.64 CPB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.64 CPB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.64 ACVRL1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.64 CPB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.64 ACVRL1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.64 ACVRL1 CPB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.64 ACVRL1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.64 ACVRL1 CPB1

MGI Mouse Phenotypes related to Tricuspid Valve Insufficiency:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.02 ACVRL1 CRELD1 FBN1 PTPN11 ZIC3
Sources

Drugs & Therapeutics for Tricuspid Valve Insufficiency

About this section

Drugs for Tricuspid Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propafenone Approved Phase 4 54063-53-5 4932
2
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
3
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
4
Tolvaptan Approved Phase 4 150683-30-0 216237
5
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
6
Angiotensin II Approved, Investigational Phase 4,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Chlorthalidone Approved Phase 4 77-36-1 2732
9
Losartan Approved Phase 4 114798-26-4 3961
10
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 77-92-9 311
11 Kava Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 9000-38-8
12 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Sodium Channel Blockers Phase 4
15 Adrenergic Agents Phase 4,Phase 1
16 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
17 Diuretics, Potassium Sparing Phase 4
18 Autonomic Agents Phase 4,Phase 1
19 Anti-Arrhythmia Agents Phase 4
20 Adrenergic beta-Antagonists Phase 4
21 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Potassium Channel Blockers Phase 4
24 Neurotransmitter Agents Phase 4,Phase 1
25 Cytochrome P-450 CYP3A Inhibitors Phase 4
26 Vasodilator Agents Phase 4,Phase 2,Phase 1,Not Applicable
27 Sympatholytics Phase 4
28 Adrenergic Antagonists Phase 4
29 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2,Not Applicable
30 Sildenafil Citrate Phase 4,Phase 2,Not Applicable 171599-83-0
31 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
32 Citrate Phase 4,Phase 2,Not Applicable
33 Antihypertensive Agents Phase 4,Phase 3,Phase 2
34 Vasopressins Phase 4
35 Arginine Vasopressin Phase 4
36 Torsemide Phase 4
37 Sodium Potassium Chloride Symporter Inhibitors Phase 4
38 Hormones Phase 4
39 Natriuretic Agents Phase 4
40 diuretics Phase 4
41 Calcium, Dietary Phase 4
42 Anticoagulants Phase 4
43 Chelating Agents Phase 4
44 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2
45 Angiotensinogen Phase 4,Phase 2
46 Angiotensin Receptor Antagonists Phase 4,Phase 2
47 calcium channel blockers Phase 4
48 Sodium Chloride Symporter Inhibitors Phase 4
49
Iodine Approved, Investigational Phase 3 7553-56-2 807
50
Treprostinil Approved, Investigational Phase 3 81846-19-7 54786 6918140

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
2 Tricuspid Regurgitation Study Completed NCT01093001 Phase 4
3 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
4 Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction Completed NCT02133352 Phase 4 Ranolazine
5 Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
6 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension Completed NCT01642407 Phase 4 Sildenafil
7 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER) Recruiting NCT02339974 Phase 4
8 Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Recruiting NCT03666351 Phase 4 Amlodipine 5mg;Losartan;Losartan and Amlodipine;Amlodipine/Losartan/Chlorthalidone;current treatment
9 Minimally Invasive Transthoracic Device Closure in Perimembranous Ventricular Septal Defect Unknown status NCT02644330 Phase 2, Phase 3
10 Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network Completed NCT00115934 Phase 3
11 Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) Completed NCT00147199 Phase 3 Inhaled treprostinil;Placebo inhalation solution
12 Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride Recruiting NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
13 Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL) Terminated NCT02387697 Phase 2, Phase 3
14 NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients Completed NCT00809094 Phase 2 N-acetylcysteine (NAC);Placebo
15 LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction Completed NCT00887588 Phase 2 LCZ696;Valsartan;Placebo
16 The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis Completed NCT00630864 Phase 2 Fx-1006A
17 Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System Recruiting NCT03331380 Phase 1, Phase 2
18 A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism Recruiting NCT03108833 Phase 2 Recombinant Human Prourokinase;Alteplase
19 Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Recruiting NCT03466333 Phase 2 Enalapril Maleate;Placebo oral capsule
20 Preventive Approach to Congenital Heart Block With Hydroxychloroquine Recruiting NCT01379573 Phase 2 Hydroxychloroquine
21 Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) Recruiting NCT03525418 Phase 1, Phase 2
22 Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension Active, not recruiting NCT02951429 Phase 2 Pirfenidone;Placebo;Sildenafil
23 Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Active, not recruiting NCT03274076 Phase 1, Phase 2 Tofacitinib;Placebo Oral Tablet
24 A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis Terminated NCT01629667 Phase 2
25 Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch Systemâ„¢ Completed NCT02098200 Phase 1
26 Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease Completed NCT01895998 Phase 1 Albuterol
27 Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study Completed NCT01571037 Phase 1 Inhaled, nebulized, Milrinone;inhaled nebulized milrinone
28 Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers Completed NCT01673555 Phase 1 GSK1278863;Placebo
29 Study of GSK2586881 on Acute Hypoxia and Exercise Recruiting NCT03000686 Phase 1
30 Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome Recruiting NCT02398604 Phase 1 Allo-hMSCs;Placebo
31 Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. Not yet recruiting NCT03406884 Phase 1 c-kit+ cells;Placebo
32 Ring Versus Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases Unknown status NCT02721524 Not Applicable
33 Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart Unknown status NCT01444222
34 MitraClip for Severe TR Unknown status NCT02863549 Not Applicable
35 The Impact of Right Ventricular Pacing on Tricuspid Regurgitation Unknown status NCT00419354
36 Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery Unknown status NCT01580436 Not Applicable
37 Long-term Outcome After Isolated Tricuspid Valve Repair Unknown status NCT01537458
38 Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients Unknown status NCT00772135 Not Applicable sildenafil citrate
39 Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ? Unknown status NCT01947257 Not Applicable
40 Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease Unknown status NCT00434902
41 Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation Completed NCT01246947 Not Applicable
42 Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation Completed NCT01203137
43 The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease Completed NCT01246141
44 Prophylactic Tricuspid Annuloplasty During Mitral Valve Surgery Completed NCT03604484 Not Applicable
45 EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty Completed NCT01532921
46 Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial Completed NCT01585779
47 Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients Completed NCT01023451
48 Acute Normovolemic Hemodilution on Serum-creatinine Concentration in Cardiac Surgery Completed NCT02831270 hydroxyethyl starch (HES 130/0.6)
49 Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery Completed NCT02502448 Not Applicable hydroxyethyl starch (HES 130/0.6)
50 Long Term Effects of Erythrocyte Lysis Completed NCT00842621

Search NIH Clinical Center for Tricuspid Valve Insufficiency

Cochrane evidence based reviews: tricuspid valve insufficiency

Sources

Genetic Tests for Tricuspid Valve Insufficiency

About this section

Genetic tests related to Tricuspid Valve Insufficiency:

# Genetic test Affiliating Genes
1 Tricuspid Regurgitation 29
Sources

Anatomical Context for Tricuspid Valve Insufficiency

About this section

MalaCards organs/tissues related to Tricuspid Valve Insufficiency:

41
Heart, Liver, Brain, Bone, Lung, Bone Marrow, Thyroid
Sources

Publications for Tricuspid Valve Insufficiency

About this section

Articles related to Tricuspid Valve Insufficiency:

(show top 50) (show all 1034)
# Title Authors Year
1
Congenital tricuspid valve disease can masquerade as primary idiopathic tricuspid regurgitation. ( 29748394 )
2018
2
Severe tricuspid regurgitation and seizure on postpartum day 10: case report of late postpartum eclampsia. ( 29451101 )
2018
3
Acute liver failure with extreme hyperbilirubinemia secondary to endocarditis-related severe mitral and tricuspid regurgitation: a challenge and an opportunity for surgeons. ( 29607182 )
2018
4
Ascending Aortic Aneurysm Causing Right Ventricular Outflow Tract Obstruction and Severe Tricuspid Regurgitation. ( 28778776 )
2018
5
A case of medical management of tricuspid regurgitation related to atrial fibrillation with constrictive pericarditis-like hemodynamics. ( 30416619 )
2018
6
Tricuspid Regurgitation Pressure Gradient as a Useful Predictor of Adverse Cardiovascular Events and All-Cause Mortality in Patients With Atrial Fibrillation. ( 30219157 )
2018
7
Valvular heart disease: tricuspid regurgitation is the new frontier. ( 30321339 )
2018
8
Functional Tricuspid Regurgitation in Mitral Valve Disease. ( 30382771 )
2018
9
Tricuspid regurgitation caused by right ventricle compression by pectus excavatum. ( 30217131 )
2018
10
Tricuspid Regurgitation Peak Gradient (TRPG)/Tricuspid Annulus Plane Systolic Excursion (TAPSE)　- A Novel Parameter for Stepwise Echocardiographic Risk Stratification in Normotensive Patients With Acute Pulmonary Embolism. ( 29375106 )
2018
11
Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement. ( 29960993 )
2018
12
Clinical Outcome of Isolated Tricuspid Regurgitation in Patients with Preserved Left Ventricular Ejection Fraction and Pulmonary Hypertension. ( 29191730 )
2018
13
Treatment of tricuspid regurgitation and para-ring leak in tetralogy of Fallot with oversized SAPIEN 3 valve-in-ring implantation. ( 29998581 )
2018
14
Improvement of tricuspid regurgitation after transcatheter ASD closure in older patients. ( 28725996 )
2018
15
Progression of Functional Tricuspid Regurgitation With Aortic Valve Stenosis After Intervention. ( 29515048 )
2018
16
Fatal heart failure caused by severe pulmonary regurgitation, tricuspid regurgitation and late-onset mitral stenosis in an adult patient with Noonan syndrome: a case report. ( 30012103 )
2018
17
Tricuspid annulus diameter does not predict the development of tricuspid regurgitation after mitral valve repair for mitral regurgitation due to degenerative diseases. ( 29478744 )
2018
18
Predictors of residual tricuspid regurgitation after percutaneous closure of atrial septal defect. ( 29905827 )
2018
19
Effect of ventricular pacing lead position on tricuspid regurgitation: A randomized prospective trial. ( 29496605 )
2018
20
Association of Tricuspid Regurgitation With Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. ( 29502934 )
2018
21
Prognostic relevance of mitral and tricuspid regurgitation in patients with severe aortic stenosis. ( 29506023 )
2018
22
Caval Valve Implantation for Treatment of Severe Tricuspid Regurgitation. ( 29519359 )
2018
23
Excessive movement of the coronary sinus lead of CRT-D and severe tricuspid regurgitation. ( 29521325 )
2018
24
Spiral suspension, a novel repair technique for severe functional tricuspid regurgitation. ( 29530578 )
2018
25
Transcatheter therapies for tricuspid regurgitation: coaptation augmentation devices. ( 29546746 )
2018
26
Prevalence and Prognostic Significance of Functional Mitral and Tricuspid Regurgitation Despite Preserved Left Ventricular Ejection Fraction in Atrial Fibrillation Patients. ( 29553091 )
2018
27
Correlation of tricuspid regurgitation and new pacemaker implantation in patients undergoing transcatheter aortic valve implantation. ( 29572082 )
2018
28
Prognostic Usefulness of Tricuspid Annular Diameter for Cardiovascular Events in Patients With Tricuspid Regurgitation of Moderate to Severe Degree. ( 29580628 )
2018
29
Outcomes After Surgical Treatment of Severe Tricuspid Regurgitation in a Contemporary Series. ( 29588136 )
2018
30
Transcatheter Treatment of Functional Tricuspid Regurgitation Using the Trialign Device. ( 29593830 )
2018
31
Evaluation of Pulmonary Artery Pressure Measurements in Severe Pulmonic Valve Insufficiency in the Absence of Tricuspid Regurgitation. ( 29611827 )
2018
32
Tricuspid Regurgitation Due to Absent Tricuspid Valve Leaflet: Utility of Three-Dimensional Echocardiography. ( 29611828 )
2018
33
Transcatheter treatment of tricuspid regurgitation using edge-to-edge repair: procedural results, clinical implications and predictors of success. ( 29633941 )
2018
34
Recent advances in managing tricuspid regurgitation. ( 29636903 )
2018
35
4D flow MRI quantification of mitral and tricuspid regurgitation: Reproducibility and consistency relative to conventional MRI. ( 29638024 )
2018
36
Transcatheter tricuspid valve edge-to-edge repair for severe tricuspid regurgitation in a Chinese patient. ( 29682008 )
2018
37
Successful repair of neonatal tricuspid regurgitation due to chordae rupture. ( 29707370 )
2018
38
"Guidelines Recommendations on the Treatment of Tricuspid Regurgitation. Where Are We and Where Do We Go With Transcatheter Valve Intervention". ( 29707544 )
2018
39
Atrial fibrillation deteriorates tricuspid regurgitation following implantable cardioverter defibrillator lead placement in patient with hypertrophic obstructive cardiomyopathy. ( 29721122 )
2018
40
One-year results of transcatheter treatment of severe tricuspid regurgitation using the edge-to-edge repair technique. ( 29741485 )
2018
41
Severe tricuspid regurgitation due to interactions with right ventricular permanent pacemaker or defibrillator leads. ( 29757467 )
2018
42
Balancing risk versus reward in isolated repair of severe tricuspid regurgitation. ( 29759736 )
2018
43
A subclinical high tricuspid regurgitation pressure gradient independent of the mean pulmonary artery pressure is a risk factor for the survival after living donor liver transplantation. ( 29764373 )
2018
44
Large animal model of acute right ventricular failure with functional tricuspid regurgitation. ( 29776560 )
2018
45
Improvement of the Left Ventricular Function after Tricuspid Valve Plasty for Traumatic Tricuspid Regurgitation. ( 29780143 )
2018
46
Diastolic Tricuspid Regurgitation Related to Atrial Systole With a Bileaflet Mechanical Valve. ( 29794376 )
2018
47
When should we assess tricuspid regurgitation severity? Preoperatively, while the patient is awake. ( 29884494 )
2018
48
Tricuspid Regurgitation - Medical Management and Evolving Interventional Concepts. ( 29892601 )
2018
49
Predictors of Persistent Tricuspid Regurgitation After Transcatheter Aortic Valve Replacement in Patients With Baseline Tricuspid Regurgitation. ( 29912741 )
2018
50
Predictors of Procedural and Clinical Outcomes in Patients With Symptomatic Tricuspid Regurgitation Undergoing Transcatheter Edge-to-Edge Repair. ( 29929631 )
2018
Sources

Variations for Tricuspid Valve Insufficiency

About this section

ClinVar genetic disease variations for Tricuspid Valve Insufficiency:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GATA4 NM_002052.4(GATA4): c.1273G> A (p.Asp425Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs56208331 GRCh37 Chromosome 8, 11615928: 11615928
2 GATA4 NM_002052.4(GATA4): c.1273G> A (p.Asp425Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs56208331 GRCh38 Chromosome 8, 11758419: 11758419
3 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh37 Chromosome 12, 112888168: 112888168
4 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh38 Chromosome 12, 112450364: 112450364
5 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh38 Chromosome 16, 15724166: 15724166
6 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh37 Chromosome 16, 15818023: 15818023
Sources

Expression for Tricuspid Valve Insufficiency

About this section
Search GEO for disease gene expression data for Tricuspid Valve Insufficiency.
Sources

Pathways for Tricuspid Valve Insufficiency

About this section
Sources

GO Terms for Tricuspid Valve Insufficiency

About this section

Cellular components related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.1 ALB CA6 CPB1 FBN1 NPPB PAPPA

Biological processes related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.13 ALB FBN1 PAPPA
2 regulation of blood pressure GO:0008217 8.8 ACVRL1 MC3R NPPB
Sources

Sources for Tricuspid Valve Insufficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....